BioCryst Pharmaceuticals, Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Charles K. Gayer
- Full Time Employees
- 435
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- 4505 Emperor Boulevard Durham NC United States 27703
- IPO Date
- Mar 4, 1994
- CIK
- 0000882796
- Website
- biocryst.com
- Similar Companies
- Business
- BioCryst Pharmaceuticals, Inc. is a biotechnology company specializing in the development and commercialization of oral small-molecule and protein therapeutics primarily targeting rare diseases. The company's core products include ORLADEYO (berotralstat), an oral plasma kallikrein inhibitor used for the prophylaxis and treatment of hereditary angioedema (HAE) in adults and pediatric patients 12 years and older; RAPIVAB (peramivir injection), an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza; and various pipeline candidates such as BCX9930, an oral Factor D inhibitor for complement-mediated diseases, and BCX9250, an oral ALK-2 inhibitor for fibrodysplasia ossificans progressiva (FOP). BioCryst's commercial offerings focus on rare genetic and complement system diseases, with ongoing clinical programs advancing novel therapies for conditions including Netherton syndrome and diabetic macular edema (DME). Founded in 1986 and headquartered in Durham, North Carolina, BioCryst operates globally, with a strategic emphasis on expanding access to its therapies worldwide. The company targets specialty healthcare providers and patients afflicted by rare and serious conditions, leveraging advanced medicinal chemistry and biological sciences to deliver transformative oral and injectable drugs. Recent major company developments include the completion of the sale of its European ORLADEYO business as part of a strategic refocus on core markets, and ongoing regulatory activities such as the FDA's review of ORLADEYO oral granules for pediatric use with an expected decision in December 2025. This pediatric indication expansion aims to broaden the accessible patient population significantly. BioCryst also reported a robust revenue increase driven by ORLADEYO, projecting full-year 2024 revenues of approximately $450.7 million and targeting profitability milestones by the end of 2025. The company is advancing its pipeline with clinical data expected in 2025 from programs such as BCX17725 for Netherton syndrome and avoralstat for DME. Additionally, BioCryst entered a $700 million acquisition deal for Astria, underscoring its commitment to deepening its rare disease portfolio. BioCryst continues to emphasize a people-focused approach alongside scientific innovation to meet unmet medical needs in hereditary angioedema and other rare disease areas. Its goal is to sustain strong growth of ORLADEYO while diversifying its pipeline toward market expansion and long-term profitability.
Company News
BioCryst to Report Third Quarter 2026 Financial Results on November 4
BioCryst Announces U.S. FDA Approval of ORLADEYO® 150 mg Oral Pellets for Adults and Adolescents with HAE
Contrasting BioCryst Pharmaceuticals (NASDAQ:BCRX) & Syndax Pharmaceuticals (NASDAQ:SNDX)
BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth
BioCryst Pharmaceuticals (NASDAQ:BCRX) and BioXcel Therapeutics (NASDAQ:BTAI) Financial Contrast
Biopharma Stock With Layers of Technical Support in Place
BioCryst Eyes $1B Rare-Disease Future Through External Innovation
4 Biotech Stocks to Watch as Potential Takeover Targets
BioCryst Pharmaceuticals, Inc. (BCRX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
BioCryst Pharmaceuticals: Why The Selloff Could Be An Opportunity
Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It
BioCryst to Present at Upcoming Investor Conference
Canada Pension Plan Investment Board Buys Shares of 115,805 BioCryst Pharmaceuticals, Inc. $BCRX
Is BioCryst Pharmaceuticals (BCRX) Stock Outpacing Its Medical Peers This Year?
BioCryst Pharmaceuticals: Owning Both Sides Of The HAE Preference Curve
Wall Street Analysts Think BioCryst (BCRX) Could Surge 108.21%: Read This Before Placing a Bet
BioCryst is profitable. Now it wants to buy more rare disease drugs
ADAR1 Capital Management LLC Takes $1.33 Million Position in BioCryst Pharmaceuticals, Inc. $BCRX
BioCryst Announces Approval of ORLADEYO® for Pediatric HAE Patients in Japan
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Average Rating of “Moderate Buy” from Brokerages